<DOC>
	<DOCNO>NCT02179710</DOCNO>
	<brief_summary>Real-world adherence inhale oral therapy cystic fibrosis ( CF ) patient remain discouragingly low , range 31-53 % inhaled antibiotic 41-72 % hypertonic saline . Programs enhance adherence , include comprehensive behavioral intervention adolescent , meet mixed success . Advances therapy , treatment delivery system , data capture technology offer potential enhancing adherence provide immediate frequent feedback patient regard fidelity prescribe treatment regimen . We propose conduct proof-of-concept study evaluate systematic approach link treatment feedback component enhance adherence .</brief_summary>
	<brief_title>Cystic Fibrosis Treatment Adherence Cayston Proof-of-Concept Pilot Study</brief_title>
	<detailed_description>Study Design : This single group intervention involve 28-day baseline ( Phase 1 ) , 28-day treatment period enhance adherence feedback . Subjects treat Cayston via blue tooth enable nebulizer .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Aztreonam</mesh_term>
	<criteria>Subjects 18 nonadherent CF patient Stratified age adult supervise ( 812 ) adolescent ( 1218 ) young adult ( 1930 ) gender Balanced ethnicity disease severity Nonadherence status determine screen base MAQ score &lt; 6 . Inability give inform consent assent</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>adherence</keyword>
	<keyword>cystic fibrosis</keyword>
	<keyword>adolescent</keyword>
	<keyword>adult</keyword>
</DOC>